Page 1 | Search Results | Blood | American Society of Hematology

1-20 of 36

Sort by

Sort Order Select

Journal Articles

Exposure to Ibritumomab Tiuxetan and Incidence of Treatment-Related Myeloid Neoplasms Among Older Patients with B-Cell Lymphoma: A Population-Based Study

Mengyang Di, MD PhD, Thomas A Ollila, MD, Adam J Olszewski, MD

Blood (2019) 134 (Supplement_1): 3477.

https://doi.org/10.1182/blood-2019-121959

Published: 2019

Journal Articles

The Dual Cell Cycle Kinase Inhibitor JNJ-7706621 Reverses Resistance to CD37 Targeted Radioimmunotherapy in Activated B Cell like Diffuse Large B Cell Lymphoma Cell Lines

Gro Elise Rødland, PhD, Katrine Melhus, Roman Generalov, Sania Gilani, Francesco Bertoni, MD, Jostein Dahle, PhD, Randi Syljuåsen, PhD, Sebastian Patzke, PhD

Blood (2019) 134 (Supplement_1): 2574.

https://doi.org/10.1182/blood-2019-123287

Published: 2019

Journal Articles

Comparative Analysis of Total Body Irradiation (TBI)-Based and Non-TBI-Based Myeloablative Conditioning for Acute Myeloid Leukemia in Remission with and without Measurable Residual Disease

Evandro D. Bezerra, MD, Linde M Morsink, MD, Megan Othus, PhD, Brent L Wood, MD PhD, Min Fang, MD PhD, Brenda M Sandmaier, MD, Marco Last Mielcarek, MD, H. Joachim Deeg, MD, H Gary Schoch, Frederick R. Appelbaum, MD, Roland B. Walter, MD PhD MS

Blood (2019) 134 (Supplement_1): 321.

https://doi.org/10.1182/blood-2019-126364

Published: 2019

Journal Articles

Potentially Cured Follicular Lymphoma (PC-FL). an Analysis of 56 Cases with Prognostic Factors Evaluation

Samantha Ferrari, MD, Alessandra Tucci, Gloria Valimberti, MD, Antonella Anastasia, MD, Chiara Bottelli, MD, Marta Petullà, Marina Motta, MD, Angela Passi, MD, Giuseppe Rossi, MD

Blood (2018) 132 (Supplement 1): 5328.

https://doi.org/10.1182/blood-2018-99-114896

Published: 2018

Journal Articles

Cell Cycle Kinase Inhibitors Potentiate the Effect of 177 lu-Lilotomab Satetraxetan in Treatment of Aggressive Diffuse Large B-Cell Lymphoma Cell Lines

Gro Elise Rødland, PhD, Katrine Melhus, Jostein Dahle, PhD, Randi Syljuåsen, PhD, Sebastian Patzke, PhD

Blood (2018) 132 (Supplement 1): 1371.

https://doi.org/10.1182/blood-2018-99-110200

Published: 2018

Journal Articles

Copper 64–labeled daratumumab as a PET/CT imaging tracer for multiple myeloma

Blood (2018) 131 (7): 741–745.

https://doi.org/10.1182/blood-2017-09-807263

Published: 2018

Includes: Multimedia, Supplemental data

Journal Articles

A Phase 2 Study of Actinium-225 ( 225 Ac)-Lintuzumab in Older Patients with Previously Untreated Acute Myeloid Leukemia (AML) Unfit for Intensive Chemotherapy

Laura E. Finn, MD, Moshe Levy, MD, Johnnie J. Orozco, MD PhD, Jae H. Park, MD, Ehab Atallah, MD, Michael Craig, MD, Alexander E. Perl, MD, David A. Scheinberg, MDPhD, Dragan Cicic, MD, Gregory Richard Bergonio, MSc, BSN, Mark S. Berger, MD, Joseph G. Jurcic, MD

Blood (2017) 130 (Supplement 1): 2638.

https://doi.org/10.1182/blood.V130.Suppl_1.2638.2638

Published: 2017

Journal Articles

Therapy with Ibritumomab Tiuxetan (Zevalin ® ) in Patients with Previously Untreated and Relapsed Low Grade Follicular Lymphoma: The Mayo Clinic Florida Experience, 2000-2016

Aixa Elena Soyano, MD, Ryan D Frank, MS, Han W Tun, MD, Jennifer Peterson, MD

Blood (2016) 128 (22): 5324.

https://doi.org/10.1182/blood.V128.22.5324.5324

Published: 2016

Journal Articles

Phase I Trial of Targeted Alpha-Particle Therapy with Actinium-225 ( 225 Ac)-Lintuzumab and Low-Dose Cytarabine (LDAC) in Patients Age 60 or Older with Untreated Acute Myeloid Leukemia (AML)

Joseph G. Jurcic, MD, Moshe Yair Levy, MD, Jae H. Park, MD, Farhad Ravandi, MD, Alexander E. Perl, MD, John M. Pagel, MD PhD, B. Douglas Smith, MD, Elihu H. Estey, MD, Hagop Kantarjian, MD, Dragan Cicic, MD, David A. Scheinberg, MD PhD

Blood (2016) 128 (22): 4050.

https://doi.org/10.1182/blood.V128.22.4050.4050

Published: 2016

Journal Articles

In-Vivo Purging with Rituximab (R) Followed By Z/BEAM Vs BEAM/R Autologous Stem Cell Conditioning for Relapsed Diffuse Large B-Cell Lymphoma (DLBCL) Patients (pts): Mature Results from a Combined Analysis of 3 Trials

Blood (2015) 126 (23): 3192.

https://doi.org/10.1182/blood.V126.23.3192.3192

Published: 2015

Journal Articles

A Phase I Study of 177 lu-DOTA-HH1 (Betalutin) Radioimmunotherapy for Patients with Relapsed CD37+ Non-Hodgkin's B Cell Lymphoma

Arne Kolstad, MD PhD, Ulf Madsbu, MD, Jostein Dahle, PhD, Caroline Stokke, PhD, Tore Bach-Gansmo, MD PhD, Ayca Muftuler Løndalen, MD, Jon Erik Holtedahl, MSc, Mona Elisabeth Revheim, MD PhD, Øyvind Bruland, MD PhD, Bjørg Bolstad, MSc, Nils Bolstad, MD, Anne Tierens, MD PhD, Roy Hartvig Larsen, PhD, Jan Alan Alfheim, MSC, MBA, Jan Delabie, MD PhD, Spetalen Signe, MD, Martin Erlanson, MD PhD, Stine Nygaard Rudå, Harald Holte, MD PhD

Blood (2014) 124 (21): 3094.

https://doi.org/10.1182/blood.V124.21.3094.3094

Published: 2014

Journal Articles

Advances in the treatment of hematologic malignancies using immunoconjugates

Maria Corinna Palanca-Wessels, Oliver W. Press

Blood (2014) 123 (15): 2293–2301.

https://doi.org/10.1182/blood-2013-10-492223

Published: 2014

Journal Articles

Yttrium-90-Ibritumomab Tiuxetan (Zevalin) Radioimmunotherapy After Cytoreduction With ESHAP Chemotherapy In Patients With Relapsed Follicular Non-Hodgkin’s Lymphoma (NHL): Interim Results Of a Phase II Study

Soham D. Puvvada, MD, Daniel O. Persky, MD, Lora Inclan, Jonathan H. Schatz, MD, Ellen M Chase, Jose Guillen, D Roe, Thomas P. Miller, MD

Blood (2013) 122 (21): 4404.

https://doi.org/10.1182/blood.V122.21.4404.4404

Published: 2013

Journal Articles

What Is the Best Combination of First-Line and Salvage Treatments in Follicular Lymphoma? Results of the Multicenter Study “Refoll” by the Fondazione Italiana Linfomi (FIL) On 548 Patients

Blood (2012) 120 (21): 154.

https://doi.org/10.1182/blood.V120.21.154.154

Published: 2012

Journal Articles

Evaluation of a Risk-Based Algorithm for the Utilization of Plerixafor As Primary Mobilization of CD34+ Cells in Autologous Hematopoietic Cell Transplant Candidates,

Jamie Shapiro, PharmD, Janelle Perkins, PharmD, Ryan Bookout, PharmD, Rebecca Tombleson, PharmD, Ernesto Ayala, MD, William E. Janssen, PhD, Claudio Anasetti, MD, Hugo F. Fernandez, MD

Blood (2011) 118 (21): 4060.

https://doi.org/10.1182/blood.V118.21.4060.4060

Published: 2011

Journal Articles

Conventional Anti-CD45 Radioimmunotherapy Comparing 90 Y or 177 Lu for Treatment of AML in a Syngeneic Disseminated Murine Leukemia Model,

Johnnie J. Orozco, MD, PhD, Aimee Kenoyer, Amanda Axtman, Shani L. Frayo, BS, Paul J. Morris, Donald K. Hamlin, D. Scott Wilbur, PhD, Darrell R. Fisher, PhD, Mark D. Hylarides, PhD, Damian J. Green, MD, Ajay K. Gopal, MD, Ted Gooley, Oliver W. Press, MD, PhD, John M. Pagel, MD, PhD

Blood (2011) 118 (21): 3636.

https://doi.org/10.1182/blood.V118.21.3636.3636

Published: 2011

Journal Articles

Re-Evaluation of CD37 As Target for Radioimmunotherapy of Non-Hodgkin Lymphoma,

Jostein Dahle, PhD, Ada Repetto, Camilla Sivertsen Mollatt, Katrine Brustad Melhus, Øyvind Sverre Bruland, MD, PhD, Arne Kolstad, MD, PhD, Roy Hartvig Larsen, PhD

Blood (2011) 118 (21): 3732.

https://doi.org/10.1182/blood.V118.21.3732.3732

Published: 2011

Journal Articles

The Risk of Secondary Myelodysplastic Syndrome/Acute Leukemia Following High-Dose Yttrium-90 Ibritumomab Tiuxetan Is Analogous to That Observed Following High-Dose Chemotherapy: a Matched-Pair Analysis In Non-Hodgkin Lymphoma Patients.

Anna Guidetti, MD, Carmelo Carlo-Stella, MD, Marco Ruella, MD, Rosalba Miceli, MD, Liliana Devizzi, MD, Daniela Sia, PhD, Silvia Locatelli, PhD, Arianna Giacomini, PhD, Michele Magni, MD, Paola Matteucci, MD, Stefano Buttiglieri, PhD, Alessandra Risso, PhD, Luigi Mariani, MD, Roberto Passera, PhD, Massimo Di Nicola, MD, Corrado Tarella, MD, Alessandro M. Gianni, MD

Blood (2010) 116 (21): 1289.

https://doi.org/10.1182/blood.V116.21.1289.1289

Published: 2010

Journal Articles

A re-examination of radioimmunotherapy in the treatment of non-Hodgkin lymphoma: prospects for dual-targeted antibody/radioantibody therapy

Robert M. Sharkey, Oliver W. Press, David M. Goldenberg

Blood (2009) 113 (17): 3891–3895.

https://doi.org/10.1182/blood-2008-11-188896

Published: 2009

Journal Articles

I-131-Anti-CD45 Radioimmunotherapy Effectively Targets and Treats T-Cell Non-Hodgkin’s Lymphoma

Ajay K Gopal, MD, Oliver W. Press, MD, PhD, Jonathan R Fromm, MD, PhD, Shani Wilbur, BS, John M. Pagel, MD, PhD

Blood (2008) 112 (11): 880.

https://doi.org/10.1182/blood.V112.11.880.880

Published: 2008

NARROW

Exposure to Ibritumomab Tiuxetan and Incidence of Treatment-Related Myeloid Neoplasms Among Older Patients with B-Cell Lymphoma: A Population-Based Study

The Dual Cell Cycle Kinase Inhibitor JNJ-7706621 Reverses Resistance to CD37 Targeted Radioimmunotherapy in Activated B Cell like Diffuse Large B Cell Lymphoma Cell Lines

Comparative Analysis of Total Body Irradiation (TBI)-Based and Non-TBI-Based Myeloablative Conditioning for Acute Myeloid Leukemia in Remission with and without Measurable Residual Disease

Potentially Cured Follicular Lymphoma (PC-FL). an Analysis of 56 Cases with Prognostic Factors Evaluation

Cell Cycle Kinase Inhibitors Potentiate the Effect of 177 lu-Lilotomab Satetraxetan in Treatment of Aggressive Diffuse Large B-Cell Lymphoma Cell Lines

Copper 64–labeled daratumumab as a PET/CT imaging tracer for multiple myeloma

A Phase 2 Study of Actinium-225 ( 225 Ac)-Lintuzumab in Older Patients with Previously Untreated Acute Myeloid Leukemia (AML) Unfit for Intensive Chemotherapy

Therapy with Ibritumomab Tiuxetan (Zevalin ® ) in Patients with Previously Untreated and Relapsed Low Grade Follicular Lymphoma: The Mayo Clinic Florida Experience, 2000-2016

Phase I Trial of Targeted Alpha-Particle Therapy with Actinium-225 ( 225 Ac)-Lintuzumab and Low-Dose Cytarabine (LDAC) in Patients Age 60 or Older with Untreated Acute Myeloid Leukemia (AML)

In-Vivo Purging with Rituximab (R) Followed By Z/BEAM Vs BEAM/R Autologous Stem Cell Conditioning for Relapsed Diffuse Large B-Cell Lymphoma (DLBCL) Patients (pts): Mature Results from a Combined Analysis of 3 Trials

A Phase I Study of 177 lu-DOTA-HH1 (Betalutin) Radioimmunotherapy for Patients with Relapsed CD37+ Non-Hodgkin's B Cell Lymphoma

Advances in the treatment of hematologic malignancies using immunoconjugates

Yttrium-90-Ibritumomab Tiuxetan (Zevalin) Radioimmunotherapy After Cytoreduction With ESHAP Chemotherapy In Patients With Relapsed Follicular Non-Hodgkin’s Lymphoma (NHL): Interim Results Of a Phase II Study

What Is the Best Combination of First-Line and Salvage Treatments in Follicular Lymphoma? Results of the Multicenter Study “Refoll” by the Fondazione Italiana Linfomi (FIL) On 548 Patients

Evaluation of a Risk-Based Algorithm for the Utilization of Plerixafor As Primary Mobilization of CD34+ Cells in Autologous Hematopoietic Cell Transplant Candidates,

Conventional Anti-CD45 Radioimmunotherapy Comparing 90 Y or 177 Lu for Treatment of AML in a Syngeneic Disseminated Murine Leukemia Model,

Re-Evaluation of CD37 As Target for Radioimmunotherapy of Non-Hodgkin Lymphoma,

The Risk of Secondary Myelodysplastic Syndrome/Acute Leukemia Following High-Dose Yttrium-90 Ibritumomab Tiuxetan Is Analogous to That Observed Following High-Dose Chemotherapy: a Matched-Pair Analysis In Non-Hodgkin Lymphoma Patients.

A re-examination of radioimmunotherapy in the treatment of non-Hodgkin lymphoma: prospects for dual-targeted antibody/radioantibody therapy

I-131-Anti-CD45 Radioimmunotherapy Effectively Targets and Treats T-Cell Non-Hodgkin’s Lymphoma

Email alerts

ASH Publications

American Society of Hematology

Email alerts

ASH Publications

American Society of Hematology

This Feature Is Available To Subscribers Only